In vitro toxicology of tobacco and related products

Ended Awarded Last action

Contract number
HHSF223201510001I
Awardee
Awarding agency
Task orders
7 $8,505,594 obligated

Award facts

Opportunity
  • 900000000 Solicitation number
Combined order value
$8,505,594 Current and potential, with all options
Last date to order 100% complete
Award type
Multiple award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The Food and Drug Administration awarded a multiple-award indefinite delivery contract to Lovelace Biomedical Research Institute on June 30, 2015, with a contract ceiling of $0.00 and ultimate completion date of June 30, 2018, for in vitro toxicology of tobacco and related products. The contract carries no set-aside designation.

Work is performed in Albuquerque, New Mexico. The IDIQ supports the FDA's regulatory oversight of tobacco products through preclinical research and testing services, including in vitro evaluation of toxic profiles, genotoxicity assessment, DNA adduct detection and characterization, and comparative toxicity analysis of conventional cigarettes versus electronic cigarettes.

The contract has a period of performance from June 30, 2015, through June 30, 2018. Recent delivery orders issued under this IDIQ include assessment of genotoxic potential of serially diluted whole tobacco smoke using Ames Micronucleus and PIG-A assays ($1,412,105.00, awarded September 8, 2017), detection and characterization of DNA adducts generated by tobacco flavorants in aerosol using air-liquid interface methods ($1,408,956.00, awarded September 14, 2017), cytotoxicity of common solvents used in liquid nicotine formulations ($1,149,919.00, awarded September 11, 2017), in vitro evaluation of toxic profiles of tobacco additives in a systematic tiered approach ($1,552,162.00, awarded September 14, 2016, and $1,405,301.00, awarded July 14, 2016), and comparative in vitro toxicity assessments of cigarettes versus e-cigarettes ($897,471.00 and $679,680.00, both awarded August 27, 2015). All delivery orders are firm fixed-price with no set-aside designation and place of performance in Albuquerque, New Mexico.

Task orders

Transactions

Action Obligated Date
Close Out P00006 $0
Novation Agreement P00005 $0
Exercise an Option 4 $0
Other Administrative Action 3 $0
Exercise an Option 2 $0
Other Administrative Action 1 $0
Original award $0

Quick answers

Who was awarded contract HHSF223201510001I?

HHSF223201510001I was awarded to Lovelace Biomedical Research Institute by Food and Drug Administration (Department of Health and Human Services) on June 30, 2015.

How much is contract HHSF223201510001I worth?

Orders under HHSF223201510001I have obligated $8,505,594.

How many orders have been placed under contract HHSF223201510001I?

7 orders have been placed under HHSF223201510001I, the latest on September 14, 2017.

Who can order from contract HHSF223201510001I?

HHSF223201510001I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract HHSF223201510001I part of a contract vehicle?

Yes. HHSF223201510001I is part of In Vivo Toxicology of Tobacco 2015-2020.

Was contract HHSF223201510001I competed?

The extent of competition for HHSF223201510001I was full and open competition. The government received 4 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV